CVBT: Shares Open Higher on Positive Article in February "Reader's Digest"

Ridgeland, MS, JAN 09, 2008 (EventX/Knobias.com via COMTEX) -- CVBT | news | PowerRating | PR Charts -- By Fain Hughes, fhughes@knobias.com

Shares of CardioVascular BioTherapeutics, Inc. (CVBT) opend higher on Wednesday after the Company announced that its angiogenesis therapy has been featured in the February 2008 issue of "Reader's Digest." The article, titled, "Heart Hope," refers to the therapy as a "new lease on life" for patients suffering from severe coronary heart disease who do not have any other viable treatment options.

The active pharmaceutical ingredient in the Company's drug candidates is Fibroblast Growth Factor 1 (FGF-1), which has multiple applications for the regenerative treatment of cardiovascular disease. FGF-1 141 is a human protein manufactured using a proprietay technology to facilitate the grwth of new blood vessels in the heart, tissues and organs that have been compromised by impaired blood supply, a process referred to in the scientific community as "angiogenesis."

In the article, Thomas J. Stegmann, MD, co-founder, co-president, and chief medical officer of CVBT explains, "the protein is like a seed that causes new vessels to sprout, creating a network of capillaries and small arteries."

The Company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). The Phase II trial of CVBT-141H is expected to begin in the coming months. A Phase Ib or Phase II trial to treat dermal wound healing in diabetics (CVBT-141B) is also planned to begin in 2008.

Dr. Stegmann concluded, "We are pleased about being highlighted by 'Reader's Digest' for our intensive work in the field of angiogenesis therapy. Our goal is to provide a viable treatment that gives heart disease patients hope and can return them to the quality of life they once enjoyed."

KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.

If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com

Knobias.com, LLC 601-978-3399 601-978-3675 info@knobias.com www.knobias.com/cmtx

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index